MedAdvisor Signs Pfizer for Patient Engagement Program

  1. 6.7k

    MedAdvisor Signs Pfizer for Patient Engagement Program

    • MedAdvisor signs Pfizer, the world’s largest research-based pharmaceutical company to
    deliver a patient engagement program (PEP) on its platform
    • Pfizer will use the MedAdvisor platform to deliver information and advice to patients to
    enhance and promote the safe and effective use of its medication
    • Pfizer develops, manufactures and distributes hundreds of prescription medicines, vaccines
    and over-the-counter products
    • Agreement with Pfizer and renewed programs provide strong validation of the value the
    PEPs are delivering pharmaceutical manufacturers and the Company’s ability to grow this revenue stream

    MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence
    company, is pleased to announce that it has entered into an agreement with Pfizer Australia Pty
    Limited (Pfizer) to provide a Patient Engagement Program (PEP) for one of its leading medications.

    MedAdvisor will work with Pfizer to deliver important information and guidance to patients
    prescribed with this Pfizer medication. Preparation for the program has already commenced
    and it will run for an initial period of 18 months.

    Pfizer will deliver a series of educational communications that aims to improve the patient’s quality
    use of medicines which in turn will deliver better patient health outcomes.

    Pfizer is the world's largest research-based pharmaceutical company. In Australia, it employs 1,700
    people and manufactures more than 50 prescription brands and over-the-counter medicines

    The Company will receive Patient Engagement Program revenue from Pfizer for the duration of the
    contract, further growing its PEP revenue stream. Pfizer is the ninth pharmaceutical company that
    has signed up to leverage MedAdvisor’s platform to deliver important information to patients.

    Additionally, two existing clients have renewed their PEP contracts with MedAdvisor for a further 12
    months each, further demonstrating the benefits and value being derived from the programs for
    pharmaceutical manufacturers.

    Robert Read, CEO of MedAdvisor commented: “Pfizer is one of the world’s largest and most diverse
    pharmaceutical businesses. Driving improvements in medication adherence is key to the value we
    can provide to the health of patients and the broader health system. Partnering with leading
    companies to help ensure quality use of medicines directly to patients is a key enabler.

    PEP programs are a key revenue driver in the long term for MedAdvisor.”

    1 like
  2. 3.5k

    Gassin, as usual you are late to the party (probably read Eds tweets) but for once you have highlighted a stock with potential

  3. 2.0k

    This stock should be flying. I know why its not. Pelaton Capital uselss in supporting stocks!

  4. 6.7k

    Good luck with should Breakout over 4c..on 2m vol.. on next the good announcement

    1 like
  5. 10
Your browser is too old for TopStocks and not secure. Please update your browser